指南与共识肾小球疾病

KDOQI对美国KDIGO 2024狼疮性肾炎管理指南的解读

KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
指南 / 共识 · Am J Kidney Dis · 2026-01-01

KDOQI工作组审查了KDIGO 2024狼疮性肾炎管理指南,结合美国临床实践提供实施观点。狼疮性肾炎治疗日趋个体化,联合治疗与激素减量成为趋势,新药获批及CAR-T临床试验正在改变治疗格局。该解读呈现KDIGO推荐与实践要点,并附临床实用性、实施与挑战的评注。

要点

  • KDIGO 2024狼疮性肾炎指南推荐联合治疗并倾向使用较低剂量糖皮质激素。
  • KDOQI结合美国实践对指南条款提供实施视角与挑战分析。
  • 新药获批及CAR-T临床试验正改变狼疮性肾炎及自身免疫病治疗格局。

核心结论

  • KDOQI工作组基于KDIGO 2024狼疮性肾炎指南提供美国临床实践的实施观点。
  • 狼疮性肾炎管理日益个体化,联合治疗与激素减量是当前趋势。

研究设计与样本

  • KDOQI召集工作组审查KDIGO 2024狼疮性肾炎指南的推荐声明与实践要点。

主要发现

  • KDIGO指南发布后,美国FDA批准了obrutinib用于狼疮性肾炎治疗。
  • CAR-T细胞疗法临床试验的患者入组正在改变包括系统性红斑狼疮在内的自身免疫病治疗格局。
  • 联合治疗及使用较低剂量糖皮质激素成为狼疮性肾炎管理的转变方向。

关键数值与推荐

  • KDIGO指南推荐联合治疗并倾向使用较低剂量糖皮质激素管理狼疮性肾炎。

临床怎么用

  • KDOQI解读为美国临床医生实施KDIGO指南提供临床实用性、实施与挑战的评注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis (LN). The management of LN has become increasingly individualized, and treatment options are expanding; for example, since the release of the KDIGO guideline, the US Food and Drug Administration has approved obinutuzumab in addition to belimumab and voclosporin for the treatment of LN, and the enrollment of patients in chimeric antigen receptor (CAR) T-cell therapy clinical trials is changing the treatment landscape for autoimmune diseases including systemic lupus erythematosus. The use of combination therapy and the trend toward lower doses of corticosteroids for LN management are also part of this transformation. The KDOQI work group reviewed the KDIGO guideline statements and practice points and provides perspectives for implementation within the context of clinical practice in the United States. This commentary is the product of the KDOQI work group and presents the recommendations and practice points from the KDIGO guideline, followed by commentary and brief notes on clinical utility, implementation, and challenges.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Norouzi S, Contreras GN. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Am J Kidney Dis. 2026. PMID: 42481080. doi:10.1053/j.ajkd.2026.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。